Fig. 2

Mechanism pathway of BV, displaying its internalization into the cell, and subsequently disrupting the microtubular network. This figure shows how BV is internalized into the cell. The drug, through its CD30-specific mAb, binds to CD30 outside the cell, on the cell surface. It is then internalized by endocytosis. Next, the endosome reacts with lysosomes, leading to the release of lysosomal proteases—the cathepsins in the endosome. Cathepsin-specific cleavage of the dipeptide linker occurs, leading to MMAE release. The MMAE exits the endosome and reaches the nucleus, where it binds to microtubules and triggers its anti-mitotic activity